Navigation Links
ARKRAY's GLUCOCARD® Vital and 01 Blood Glucose Meters are now on the Department of Defense Uniform Formulary.
Date:10/28/2011

EDINA, Minn., Oct. 28, 2011 /PRNewswire/ -- ARKRAY USA, Inc. (ARKRAY) announced today that the GLUCOCARD® Vital and 01 are now listed on the Department of Defense (DoD) Uniform Formulary.  The DoD Pharmacy and Therapeutic committee (P&T) selected both the GLUCOCARD® Vital and the GLUCOCARD® 01 Blood Glucose Meters as the first and second most cost effective blood glucose meters in all points of service as noted by the Uniform Formulary Beneficiary Advisory Panel (BAP) earlier this year.

Both GLUCOCARD Vital and GLUCOCARD 01 meter systems feature advanced auto coding technology and require only a tiny sample size at a cost that is less than other blood glucose meter systems on the Uniform Formulary including the current blood glucose meter offered on the Basic Core Formulary.  

"We're excited that ARKRAY has two meters on the Department of Defense Uniform Formulary," said Jonathan Chapman, President of ARKRAY. "Our GLUCOCARD meter systems offer high performance standards.  To be recognized by the DoD for having the most cost-effective blood glucose meters is an honor."

GLUCOCARD meters work with ARK Care™, a Real-Time Diabetes Data Management System.  This unique, patient focused, online software for diabetes management allows patients, healthcare providers and care givers to capture data, see results, and manage ones diabetes. Every GLUCOCARD meter is backed by our GLUCOCARD YouChoose® Wellness and Support Program. Exclusively for GLUCOCARD patients, the program provides free education and support materials, recipes, meal planners, ongoing support, and more.  

ARKRAY will be demonstrating their GLUCOCARD Blood Glucose Meters at the Joint Forces Pharmacy Seminar (JFPS) in Dallas, TX next week.  "Exhibiting at the largest annual event for the military pharmacy community is the perfect opportunity to show pharmacists and technicians first hand how our products perform for their patients with diabetes," said Robert Wernsman, Vice President of Consumer Healthcare Division.

About ARKRAY

ARKRAY has been a pioneer for over 50 years in the field of automated analysis from laboratory and point-of-care systems to home use patient self testing systems. ARKRAY invests heavily in R&D and has a strong commitment to high-quality products. ARKRAY is the company that developed the world's commercially successful portable blood glucose analyzer in the early 1970s and the world's first A1C analyzer in 1982.


'/>"/>
SOURCE ARKRAY USA, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial
2. BD to Increase Access to Vital Cervical Cancer Screening in Resource-Limited Settings Through Commitment to Pink Ribbon Red Ribbon Initiative®
3. SAIC Completes Acquisition of Vitalize Consulting Solutions, Inc.
4. ConvaTec Presents New Data on ConvaTec Moldable Technology™ and Vitala™ Continence Control Device in Ostomy Care
5. Recall of Infant and Neonatal-Sized FilterLine H Set and VitaLine H Set Sampling Lines
6. AT&T Connected Vitality GlowCaps Wins 2011 Global Mobile Award
7. Vitalitec Acquires ENCLOSE II Anastomosis Assist Device
8. Dr. F. Stockmans, One of the Earliest Proponents of Materialises Surgicase(R) Orthopaedics, States the Case for its Vital Role in the Treatment of Distal Radius Malunions at ASSH 2010
9. FUJIFILM Revitalizes Images of Health Breast Cancer Awareness Initiative
10. Honoring Those Who Collect Blood, Medicines Most Vital Natural Resource
11. Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):